Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year

Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year
Press Release | Jun 26. 2019 17:57 GMT

Chr. Hansen delivers a solid financial result of 9% organic growth for the first nine months, but adjusts full-year organic growth outlook from 9-11% to 7-8%

Solid organic revenue growth of 9% in the first nine months of 2018/19: Food Cultures & Enzymes 9%, Health & Nutrition 11% and Natural Colors 4%. Currencies impacted Euro growth negatively by 2%. EBIT before special items increased by 10% to EUR 241 million, corresponding to an EBIT margin before special items of 28.2% up 0.7%-point compared to last year. In Q3, organic growth was 8%, and EBIT before special items increased by 9%. Organic growth outlook for 2018/19 is adjusted to 7-8%, whereas the guidance on EBIT is unchanged and the guidance on FCF is adjusted upwards.

CEO Mauricio Graber says: “We delivered a solid Q3 result despite more challenging trading conditions, mainly in emerging markets. Performance in Food Cultures & Enzymes continues to be in line with expectations and we are progressing well on our strategic agenda of delivering new innovative solutions to customers, so we can continue to grow solidly and profitably, even in markets with lower volume growth momentum. In Q3, organic growth in Bioprotection increased to around 15%, an acceleration from Q2, and we’ve launched SWEETY®, a new culture that allows dairies to reduce added sugar by up to 20%. In Health & Nutrition, the business accelerated from Q2, and the 11% organic growth was driven by strong growth in infant formula and Plant Health. Organic growth in Animal Health was solid, although a higher momentum was expected in Q3. In Natural Colors, headwind from a poor economic environment in emerging markets was stronger than anticipated, and 3% organic growth in Q3 is below our ambition.

"Our EBIT margin before special items in the first nine months of the year increased by 0.7%-point and was driven by improved margins in all business areas. In FC&E, we’re well on track to deliver the scalability benefits from the ramp up of the new capacity in our facility in Copenhagen, while still increasing our investments in the business.

"As a result of the lower than expected growth momentum in Natural Colors and Animal Health, and a weaker growth environment in emerging markets, we are adjusting our full-year outlook from 9-11% organic growth for the group to now 7-8% organic growth. Guidance for Food Cultures & Enzymes is unchanged, Health & Nutrition is now expected to grow around 10%, and Natural Colors is now expected to grow 4-5%. The guidance on EBIT margin is unchanged. The free cash flow before acquisitions, divestments and special items is now expected to be above last year, as some investments have been moved into next year. Based on the cash-flow generation in the first nine months, the Board of Directors has decided to pay out an extraordinary dividend totaling EUR 110 million (DKK 6.24 per share).”

EUR million Q3 2018/19 Q3 2017/18 Growth YTD 2018/19 YTD 2017/18 Growth
Revenue 302.0 282.7 7% 855.2 800.9 7%
EBIT before special items 91.7 84.0 9% 241.3 219.9 10%
Profit for the period 66.5 60.5 10% 175.6 158.1 11%
Free cash flow before acquisitions and special items 48.9 64.4 (24)% 56.5 75.4 (25)%
Organic growth, % 8% 9% 9% 9%
Gross margin, % 56.6% 55.6% 55.4% 53.9%
EBIT margin before special items, % 30.4% 29.7% 28.2% 27.5%
ROIC excl. goodwill, % 37.1% 37.7% 34.3% 34.2%


OUTLOOK FOR 2018/19

The overall outlook for 2018/19 is adjusted compared to the announcement of April 3, 2019 as follows:

June 26, 2019 April 3, 2019
Organic revenue growth 7-8% 9-11%
EBIT margin before special items around 29.5% around 29.5%
Free cash flow before acquisitions, divestments and special items above last year around last year


科 汉森是一家全球性且具备差异化的生物科技公司,为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森,我们拥有独特的优势,可通过微生物解决方案推动积极的变革。 在过去超过 145 年的时间里,我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力,库存广泛且价值重大,包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外,我们还将挖掘释放有益菌的力量,以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司,我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动,公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。

共享